Table 2 Meta-analysis for studies included in the analysis Table 2 Meta-analysis for studies included in the analysis Table 2 Meta-analysis for studies included in the analysis Table 2 Meta-analysis for studies included in the analysis
Subgroup analysis Number of studies Number of estimates Pooled OR (95% CI), I2 statistics (%), P-value for the heterogeneity Q test Model used
Congennital malformations
Neuraminidase inhibitor 7 8 0.9 (0.72 - 1.12); I2 = 0%, P = 0.852 Fixed effects
Oseltamivir 6 6 0.89 (0.69 - 1.14); I2 = 0%, P = 0.745 Fixed effects
Heart malformations 2 2 1.11 (0.61 - 2.03); I2 = 0%, P = 0.405 Fixed effects
Low birth weight
Neuraminidase inhibitor 6 8 0.79 (0.68 - 0.92); I2 = 0%, P = 0.483 Fixed effects
Oseltamivir 5 6 0.84 (0.71 - 0.99); I2 = 16.2%, P = 0.309 Fixed effects
Low Apgar score
Neuraminidase inhibitor 5 6 0.96 (0.77 - 1.2); I2 = 0%, P = 0.643 Fixed effects
Oseltamivir 4 5 0.96 (0.77 - 1.2); I2 = 0%, P = 0.643 Fixed effects
SGA
Neuraminidase inhibitor 4 6 0.78 (0.69 - 0.88); I2 = 0%, P = 0.701 Fixed effects
Oseltamivir 4 6 0.77 (0.68 - 0.88); I2 = 0%, P = 0.53 Fixed effects
Preterm birth
Neuraminidase inhibitor 0.99 (0.89 - 1.09); I2 = 0%, P = 0.54 Fixed effects
Oseltamivir 7 9 1.03 (0.93 - 1.15); I2 = 0%, P = 0.447 Fixed effects